| Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED |
2021-04-08 |
| Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience |
2021-03-30 |
| Step Pharma–France (govt): investment, 202103 financing round Series B totalling €35m incl existing + co-investor Bpifrance via IBRD + InnoBio 2 funds |
2021-03-24 |
| Step Pharma–Hadean Ventures: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Hadean Ventures |
2021-03-24 |
| Step Pharma–Kurma: investment, 202103 financing round Series B totalling €35m incl existing + co-investor Kurma Partners |
2021-03-24 |
| Step Pharma–Pontifax: investment, 202103 financing round Series B totalling €35m incl existing + co-investor Pontifax |
2021-03-24 |
| Step Pharma–SEVERAL: investment, 202103 financing round Series B €35m co-led by new investors Hadean Ventures + Sunstone Life Science Ventures |
2021-03-24 |
| Step Pharma–Sunstone Life Science: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Sunstone Life Science |
2021-03-24 |
| AgomAb Therapeutics–Andera Partners: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Amdera Partners |
2021-03-10 |
| AgomAb Therapeutics–Omnes Capital: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Omnes Capital |
2021-03-10 |
| AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group |
2021-03-10 |
| Biolojic Design–Burns McClellan: public relations, 202103 service existent Burns McClellan is media contact |
2021-03-08 |
| CVasThera–SEVERAL: investment, 202103 1st financing round €1.3m led by Ocseed |
2021-03-03 |
| EG 427–ATCG Partners: public relations, 202103 service existent ATCG is EU media contact |
2021-03-01 |
| EG 427–Burns McClellan: public relations, 202103 service existent Burns McClellan is US media contact |
2021-03-01 |
| EG 427–PERSON: investment, 202103 financing round series A totalling €12m incl lead investor David Lamon with San Francisco based large family offices |
2021-03-01 |
| EG 427–SEVERAL: investment, 202103 financing round series A €12m led by David Lamon with San Francisco based large family offices |
2021-03-01 |
| French Myopathy Association–WhiteLab Genomics: genomic s/w tools, 202102– collab Généthon using Catalyst s/w to develop vectors for gene therapies |
2021-02-10 |
| CorWave–Taddeo: public relations, 202102 supply service existent by Taddeo |
2021-02-08 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| Servier–MiNA Therapeutics: saRNA therapeutics, 202101– collab research + license option for saRNA therapeutics for neurological diaseses |
2021-01-21 |
| IO Biotech–Kurma: investment, 202101 financing round Series B totalling €127m incl new + co-investor Kurma Partners |
2021-01-13 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Sanofi–Biond Biologics: antibody cancer drug, 202101– license ww excl to BND-22 anti-IgG4 antibody $125m upfront + >$1b milestones + royalties |
2021-01-12 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| CorWave–BPCE: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Seventure |
2021-01-06 |
| CorWave–EU (govt): investment, 202101 financing round Series C totalling €35m incl €15m from new investor EIC Fund |
2021-01-06 |
| CorWave–Financière Arbevel: investment, 202101 financing round Series C totalling €35m incl new + co-investor Financière Arbevel |
2021-01-06 |
| CorWave–France (govt): investment, 202101 financing round Series C totalling €35m incl existing + co-investor Bpifrance |
2021-01-06 |
| CorWave–M&L Healthcare: investment, 202101 financing round Series C totalling €35m incl new + co-investor M&L Healthcare |
2021-01-06 |
| CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings |
2021-01-06 |
| CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund |
2021-01-06 |
| CorWave–Sofinnova: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Sofinnova Partners |
2021-01-06 |
| CorWave–Ysios Capital: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Ysios Capital |
2021-01-06 |
| Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare |
2021-01-05 |
| Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare |
2021-01-05 |
| Cellectis–SEVERAL: investment, 202012 underwritten public offering of ADSs $100m+15m ANNOUNCED + WITHDRAWN |
2020-12-14 |
| InnoSkel–Consilium: public relations, 202012 service existent by Consilium Strategic Communications |
2020-12-14 |
| InnoSkel–Jeito Capital: investment, 202012 financing round Series A totalling €20m incl co-lead investor Jeito Capital |
2020-12-14 |
| InnoSkel–Région Sud (FR): investment, 202012 financing round Series A totalling €20m incl co-investor Région Sud Investissement |
2020-12-14 |
| InnoSkel–SEVERAL: investment, 202012 financing round Series A €20m co-led by Jeito Capital + Vida Ventures |
2020-12-14 |
| InnoSkel–Turenne: investment, 202012 financing round Series A totalling €20m incl co-investor The Turenne Group |
2020-12-14 |
| InnoSkel–Vida Ventures: investment, 202012 financing round Series A totalling €20m incl co-lead investor Vida Ventures |
2020-12-14 |
| MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management |
2020-12-01 |
| MaaT Pharma–France (govt): investment, 202012 financing round Series B extension totalling €7.35m incl new + lead investor PSIM Fund |
2020-12-01 |
| MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m |
2020-12-01 |
| MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science |
2020-12-01 |
| Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners |
2020-12-01 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF |
2020-11-25 |
| Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF |
2020-11-25 |
| AlgoTherapeutix–SEVERAL: investment, 202011 financing round Series A €12m led by Bpifrance InnoBio 2 fund + co-investor Omnes |
2020-11-24 |
| Catamaran Bio–SEVERAL: investment, 202011 financing round Series A $42m co-led by Sofinnova Partners + Lightstone Ventures |
2020-11-23 |
| Catamaran Bio–Sofinnova: investment, 202011 financing round Series A $42m incl co-lead investor Sofinnova Partners |
2020-11-23 |
| Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
| Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo |
2020-11-23 |
| Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund |
2020-11-23 |
| Myricx Pharma–SEVERAL: investment, 202011 seed financing round £4.5m with Sofinnova Partners + Brandon Capital Partners |
2020-11-16 |
| Myricx Pharma–Sofinnova: investment, 202011 seed financing round totalling £4.5m incl investor Sofinnova Partners |
2020-11-16 |
| Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi |
2020-11-13 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures |
2020-11-02 |
| Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| GenSight Biologics–Arix Bioscience: investment, 202010 private placement totalling €25m incl co-lead investor Arix Bioscience |
2020-10-22 |
| GenSight Biologics–France (govt): investment, 202010 private placement totalling €25m incl €1m from existing + co-investor Bpifrance Investissement |
2020-10-22 |
| GenSight Biologics–Invus Group: investment, 202010 private placement totalling €25m incl co-lead investor Invus |
2020-10-22 |
| GenSight Biologics–SEVERAL: investment, 202010 private placement €25m led by Arix Bioscience + Invus + Sofinnova Partners |
2020-10-22 |
| GenSight Biologics–Sofinnova: investment, 202010 private placement totalling €25m incl €4.5m from existing + co-lead investor Sofinnova Partners |
2020-10-22 |
| SparingVision–4BIO Ventures: investment, 202010 financing round totalling €44.5m incl new + co-lead investor 4BIO Capital |
2020-10-21 |
| SparingVision–Consilium: public relations, 202011 service existent by Consilium Strategic Communications |
2020-10-21 |
| SparingVision–Foundation Fighting Blindness: investment, 202010 financing round totalling €44.5m incl existing + co-investor FFB |
2020-10-21 |
| SparingVision–France (govt): investment, 202010 financing round totalling €44.5m incl existing + co-investor Bpifrance |
2020-10-21 |
| SparingVision–Jeito Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Jeito Capital |
2020-10-21 |
| SparingVision–SEVERAL: investment, 202010 financing round €44.5m led by 4BIO Capital + UPMC Enterprises |
2020-10-21 |
| SparingVision–Torreya: financial services, 202010 supply service Torreya Capital LLC acted as excl placement agent for €44.5m offering |
2020-10-21 |
| SparingVision–Univ Pittsburgh: investment, 202010 financing round totalling €44.5m incl new + co-lead investor UPMC Enterprises |
2020-10-21 |
| SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital |
2020-10-21 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| Carmat–France (govt): grant, 202010– grant €13m national innovation funding for clinical study of artificial heart in France from Health Ministry |
2020-10-12 |
| Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital |
2020-10-12 |
| Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP |
2020-10-12 |
| Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson |
2020-10-12 |
| Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd |
2020-10-12 |
| Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap |
2020-10-12 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC |
2020-10-12 |
| Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital |
2020-10-06 |
| Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude |
2020-10-06 |
| Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
| Ynsect–SEVERAL: investment, 202010 financing round Series C extension to total of $372m led by Astanor Ventures |
2020-10-06 |
| BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED |
2020-10-02 |
| Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth |
2020-10-01 |
| Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) |
2020-09-29 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m |
2020-09-15 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
